Abstract Library

#1760 The Efficacy and Safety of Sunitinib in Patients with Advanced Well Differentiated Pancreatic Neuroendocrine Tumors: Focus on Response Rate

Introduction: In a pivotal phase 3 study (NCT00428597) SU demonstrated a significant increase in progression-free survival (PFS) vs placebo following early study termination.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Raymond E, Kulke M, Qin S, Yu X, Schenker M,

Keywords: pNET, survival, sunitinib,

#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover

Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Raymond E

Authors: Raymond E, Niccoli P, Castellano D, Valle J, Hammel P,

Keywords: sutent, OS,

#332 Impact of Baseline Ki-67 index and Other Baseline Characteristics on Outcome in a Study of Sunitinib (SU) for the Treatment of Advanced, Progressive Pancreatic Neuroendocrine Tumor (NET)

Introduction: Baseline Ki-67 index and other characteristics may influence outcome in patients (pts) with pancreatic NET; however, the value of Ki-67 and others have not been evaluated prospectively in trials.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Raymond E, Harmon C, Niccoli P, Metrakos P, Borbath I,

Keywords: Sunitinib, phase 3, pancreatic neuroendocrine tumor, Ki-67 index, prior treatment, prognostic factor,

#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors

Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Raymond E

Authors: Raymond E, Seitz J, Bang Y, Borbath I, Lombard-Bohas C,

Keywords: Sunitinib, phase III, pancreatic neuroendocrine tumor ,